Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'On' or 'off' proton pump inhibitor?

American Journal of Gastroenterology

Volumn 103, Issue 10, 2008, Pages 2446-2453

  Hemmink, Gerrit J M ^a,b   Bredenoord, Albert J ^a   Weusten, Bas L A M ^a   Monkelbaan, Jan F ^c   Timmer, Robin ^a   Smout, André J P M ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c CENTRAL MILITARY HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; IMPEDANCE; MALE; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

ADULT; AGED; CROSS-OVER STUDIES; DRUG RESISTANCE; ELECTRIC IMPEDANCE; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MANOMETRY; MIDDLE AGED; PRESSURE; PROGNOSIS; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 53149102038     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02033.x     Document Type: Article

References (23)

1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005 54 : 710 7.
2. Locke GRr, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997 112 : 1448 56.
3. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006 101 : 1900 20.
4. Smout AJ. The patient with GORD and chronically recurrent problems. Best Pract Res Clin Gastroenterol 2007 21 : 365 78.
5. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology 2001 120 : 1599 606.
6. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006 55 : 313 8.
7. Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001 120 : 1588 98.
8. Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: New insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004 8 : 890 7 discussion 897 8.
9. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002 72 : 453 60.
10. Bredenoord AJ, Weusten BL, Timmer R, et al. Reproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux. Am J Gastroenterol 2005 100 : 265 9.
11. Aanen MC, Bredenoord AJ, Smout AJ. Reproducibility of symptom-reflux association analysis with 24-hour esophageal impedance-pH recordings. Gastroenterology 2007 132 : A472.
12. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: Review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004 53 : 1024 31.
13. Smout AJ, Breedijk M, Van Der Zouw C, et al. Physiological gastroesophageal reflux and esophageal motor activity studied with a new system for 24-hour recording and automated analysis. Dig Dis Sci 1989 34 : 372 8.
14. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: Effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996 91 : 1532 8.
15. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990 335 : 205 8.
16. Lam HG, Breumelhof R, Roelofs JM, et al. What is the optimal time window in symptom analysis of 24-hour esophageal pressure and pH data Dig Dis Sci 1994 39 : 402 9.
17. Weusten BL, Roelofs JM, Akkermans LM, et al. The symptom-association probability: An improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994 107 : 1741 5.
18. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: A multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006 55 : 1398 402.
19. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: A study in patients off and on therapy. Am J Gastroenterol 2006 101 : 1956 63.
20. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006 101 : 453 9.
21. Bredenoord AJ, Weusten BL, Timmer R, et al. Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure. Am J Gastroenterol 2006 101 : 2470 5.
22. Conchillo JM, Schwartz MP, Selimah M, et al. Acid and non-acid reflux patterns in patients with erosive esophagitis (EE) and non-erosive reflux disease (NERD): A study using intraluminal impedance monitoring. Dig Dis Sci 2008 53 : 1506 12.
23. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999 3 : 292 300.